Overview on LNP-mRNA encapsulation unit operation: Mixing technologies, scalability, and influence of formulation &...

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery

Background:

• Nanoparticles for drug delivery have evolved significantly since the 1970s.
• Lipid nanoparticles (LNPs) represent a current generation, enabling applications in vaccines and cancer therapy.
• LNPs are self-assembled, non-viral vehicles for delivering genetic materials such as RNA.

Purpose of the Study:

• To review the characteristics of LNP-encapsulated mRNA (LNP-mRNA).
• To describe various production methods for LNP-mRNA.
• To highlight challenges in mixing quality during LNP-mRNA production, particularly during scale-up.

Main Methods:

• Lipid nanoparticles are formed via rapid mixing of aqueous mRNA and organic lipid phases.
• mRNA encapsulation within LNPs occurs through electrostatic interactions with ionizable lipids.
• Continuous production methods, often utilizing T-shaped mixers, are prevalent for LNP-mRNA.

Main Results:

• T-shaped mixers are commonly employed for producing mRNA-LNPs.
• LNP production can be scaled from microfluidic chips to millimetric tubing.
• Mixing quality is a critical factor influencing LNP characteristics and production efficiency.

Conclusions:

• Understanding LNP-mRNA characteristics and production is crucial for advanced therapeutics.
• Continuous manufacturing methods offer advantages for LNP-mRNA production.
• Addressing scale-up challenges related to mixing quality is essential for robust LNP manufacturing.